MedTrace Logo

Medication Reviews in Severe Mental Illness

NCT05243160 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-09-03

No results posted yet for this study

Summary

This study aims to investigate the potential beneficial effects of a medication review by a clinical pharmacologist on patients with coexisting severe mental illness and diabetes. The study is an intervention study in which an intervention group is assigned to the medication review whereas a control group is not. Both groups are tested using an extensive test battery at baseline and 6 months after inclusion.

Furthermore a qualitative data assessment will be undertaken using interviews and/or surveys in order to show any obstacles in implementing the intervention. This is relevant as medication reviews, performed by clinical pharmacologists as well as pharmacists, are not always implemented by the primary physician.

The economic impact of the medication review will furthermore be assessed.

Conditions

Interventions

OTHER

medication review

The intervention consist of a medication review by a clinical pharmacologist.

Sponsors & Collaborators

  • Steno Diabetes Center Sjaelland

    collaborator OTHER_GOV

  • Region Zealand

    collaborator OTHER

  • Psychiatric Research Unit, Region Zealand, Denmark

    lead OTHER

Principal Investigators

  • Gesche Jürgens, MD · Consultant physician

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-11
Primary Completion
2023-10-27
Completion
2023-10-27

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05243160 on ClinicalTrials.gov